TORL BioTherapeutics, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TORL BioTherapeutics, LLC - overview
Established
2018
Location
Culver, CA, US
Primary Industry
Biotechnology
About
Founded in 2018 and based in California, US, TORL BioTherapeutics, LLC is a clinical-stage biopharmaceutical firm focused on developing antibody-based therapeutics to help cancer patients. David Licata (CEO), Dennis Slamon, Mark Attanasio, and Neil O'Brien are the co-founders of the company. In October 2025, TORL BioTherapeutics, LLC raised USD 96 million in series C funding from unspecified investors. The company provides TORL-1-23, a CLDN6-directed ADC created for patients with a variety of cancer types.
An ADC and mAb targeting CLDN 18. 2 are two further clinical-stage programmes offered by the business. TORL is also developing preclinical ADCs (antibody-drug conjugates) and mAbs (monoclonal antibodies) for oncologic indications. The company will use the October 2025 funding to advance clinical trials for its Claudin 6-targeted antibody drug and support other pipeline programs.
Current Investors
Healthcare Royalty Partners, Alexandria Venture Investments, Bristol-Myers Squibb Company
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.torlbio.com/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.